Company intelligence / Profile preview

B&C Pharma

Ownership: Private
Development stage: Other

Overview

B&C Pharma is a China-based pharmaceutical company specializing in the import and export of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, excipients, and finished formulations. The company has experience in sourcing, marketing research, sales abroad for Chinese manufacturers, and registration of APIs/formulations in overseas markets. Its only known pipeline drug candidate was BC-2125 targeting hepatitis C via NS5B polymerase inhibition; this program has been discontinued[1][2][4][5].

Therapeutic areas: Infectious Diseases
Modalities: Small molecule (APIs)Pharmaceutical intermediatesFormulations
Industry: Chemicals & Materials

Partnerships

Sourcing partnerships with manufacturers in China, India, and other countries[1]Marketing/sales partnerships for Chinese manufacturers abroad[1]

Beyond the preview

Go deeper on B&C Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B&C Pharma.

Explore the full profile